SELLAS Life Sciences Group (SLS) director awarded 50K RSUs grant

Rhea-AI Filing Summary

SELLAS Life Sciences Group director David A. Scheinberg reported receiving an equity award in the form of restricted stock units. On January 7, 2026, he was granted 50,000 restricted stock units (RSUs) of the company’s common stock at a stated price of $0.00 per share, reflecting a compensatory grant rather than a purchase. According to the award terms, these RSUs are scheduled to vest in full on December 1, 2026, provided he continues to serve on the company’s Board of Directors through that date. Following this grant, he beneficially owned 73,082 shares of SELLAS common stock in total, held directly.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

SCHEINBERG DAVID A

(Last) (First) (Middle)

C/O SELLAS LIFE SCIENCES GROUP, INC.,

7 TIMES SQUARE, SUITE 2503

(Street)

NEW YORK NY 10036

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
SELLAS Life Sciences Group, Inc. [ SLS ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
01/07/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	01/07/2026		A		50,000(1)	A	$0.00	73,082	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The Reporting Person received an award of 50,000 restricted stock units on January 7, 2026, which shall vest in full on December 1, 2026, subject to the Reporting Person's continued service on the Issuer's Board of Directors through such date.

	/s/ Daniel Bagliebter, Power of Attorney for: David A. Scheinberg	01/09/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did SLS director David A. Scheinberg report?

David A. Scheinberg reported receiving an award of 50,000 restricted stock units (RSUs) of SELLAS Life Sciences Group, Inc. common stock on January 7, 2026.

At what price were the 50,000 SELLAS (SLS) RSUs granted to the director?

The 50,000 RSUs were reported with a transaction price of $0.00 per share, indicating a compensatory equity award rather than a market purchase.

When do the 50,000 RSUs granted to the SELLAS (SLS) director vest?

The 50,000 restricted stock units granted to the director are scheduled to vest in full on December 1, 2026, subject to his continued service on the Board.

What is the vesting condition for the SELLAS (SLS) director’s RSU award?

The RSU award will vest only if the reporting person continues to serve on the Issuer's Board of Directors through December 1, 2026.

How many SELLAS (SLS) shares does the director own after this RSU grant?

After the reported transaction, the director beneficially owned 73,082 shares of SELLAS Life Sciences Group, Inc. common stock, held directly.

Is the SELLAS (SLS) director an officer or 10% owner of the company?

The reporting person is identified as a director of SELLAS Life Sciences Group, Inc. and is not listed as an officer or 10% owner.